-
Mashup Score: 3Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer - 12 hour(s) ago
Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer - 23 hour(s) ago
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer @jhaveri_komal @MSKCancerCenter @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/bhmMdWrIa1
-
-
Mashup Score: 3Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer - 3 day(s) ago
Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/sI4HOKcBUC
-
-
Mashup Score: 6Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer - 4 day(s) ago
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer @jhaveri_komal @MSKCancerCenter @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/bhmMdWrIa1
-
-
Mashup Score: 4Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer - 5 day(s) ago
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/oWEzAAl5vu
-
-
Mashup Score: 4Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC - 19 day(s) ago
Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/BlHjFd7t9Z
-
-
Mashup Score: 6Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer - 21 day(s) ago
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer @jhaveri_komal @MSKCancerCenter @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/bhmMdWrIa1
-
-
Mashup Score: 3Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer - 21 day(s) ago
Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/sI4HOKcBUC
-
-
Mashup Score: 4Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer - 21 day(s) ago
Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/oWEzAAl5vu
-
Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #medtwitter #oncology https://t.co/sI4HOKcBUC